Bioorganic and Medicinal Chemistry Letters p. 6108 - 6115 (2012)
Update date:2022-09-26
Topics:
Kers, Inger
MacSari, Istvan
Csjernyik, Gabor
Nyloef, Martin
Skogholm, Karin
Sandberg, Lars
Minidis, Alexander
Bueters, Tjerk
Malmborg, Jonas
Eriksson, Anders B.
Lund, Per-Eric
Venyike, Elisabet
Luo, Lei
Nystroem, Jan-Erik
Besidski, Yevgeni
The NaV1.7 ion channel is an attractive target for development of potential analgesic drugs based on strong genetic links between mutations in the gene coding for the channel protein and inheritable pain conditions. The (S)-N-chroman-3-ylcarboxamide series, exemplified by 1, was used as a starting point for development of new channel blockers, resulting in the phenethyl nicotinamide series. The structure and activity relationship for this series was established and the metabolic issues of early analogues were addressed by appropriate substitutions. Compound 33 displayed acceptable overall in vitro properties and in vivo rat PK profile.
View Morelianyungang jinkang pharmaceutical technology co., ltd.
Contact:008651885445517
Address:Jinshan industrial park, Ganyu county, Lianyungang, Jiangsu Province, 222115, China
Buffett (China) Holding Co.,Ltd
Contact:4006570891
Address:
TIANJIN ZHONGXIN CHEMTECH CO.,LTD.
Contact:86-022-89880739
Address:10B, Pan China International Center, No. 931 YingKou Road, TangGu, Tianjin, China, 300451
Henan Yellow River New Material Technology Co.Ltd.
website:http://www.yellowriverchem.com
Contact:0086-373-7278760
Address:Chengguan Town, Yuanyang County
Contact:+ 86 512 52491118
Address:1 Fuyu Road, Haiyu TownChangshu, Jiangsu, China
Doi:10.1248/cpb.44.1146
(1996)Doi:10.1007/s12039-012-0309-2
(2012)Doi:10.1055/s-0036-1591722
(2018)Doi:10.1016/j.ejmech.2012.09.008
(2012)Doi:10.1021/acsmedchemlett.7b00450
(2018)Doi:10.1021/jo302175g
(2012)